Company news

Share this article:

GlaxoSmithKline has inked a deal worth as much as $425 million to develop drugs for respiratory and cardiovascular disease with San Diego company Amira Pharmaceuticals. The deal will give GSK worldwide rights to develop, manufacture and sell experimental compounds including an experimental asthma treatment known as AM103, which has already has shown promise in early human trials. Amira could receive as much as $425 million in payments if it meets all of its development and regulatory milestones. It also will receive royalty payments on sales of any of its drugs.

Roska Healthcare Advertising has launched a new Web site at www.roskahealthcare.com offering visitors a virtual tour of the firm's people, clients and category experience.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.